APPLICATION
ANDA204959
TYPE
ANDA
ORIGINAL APPROVAL
2018-08-10
LATEST ACTION
2024-12-03
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
PIPERACILLIN AND TAZOBACTAMPrescription
PIPERACILLIN SODIUM EQ 4GM BASE/VIAL, TAZOBACTAM SODIUM EQ 500MG BASE/VIAL · INJECTABLE · INJECTION
PIPERACILLIN AND TAZOBACTAMPrescription
PIPERACILLIN SODIUM EQ 2GM BASE/VIAL, TAZOBACTAM SODIUM EQ 250MG BASE/VIAL · INJECTABLE · INJECTION
PIPERACILLIN AND TAZOBACTAMPrescription
PIPERACILLIN SODIUM EQ 3GM BASE/VIAL, TAZOBACTAM SODIUM EQ 375MG BASE/VIAL · INJECTABLE · INJECTION
Approval history
2024-12-03Labeling · Supplement 15 · standardAP
2024-05-01Labeling · Supplement 13 · standardAP
2024-01-03Labeling · Supplement 8 · standardAP
2024-01-03Labeling · Supplement 7 · standardAP
2022-02-15Labeling · Supplement 6 · standardAP
2021-07-22Labeling · Supplement 1 · standardAP
2021-07-22Labeling · Supplement 4 · standardAP
2018-08-10UNKNOWN · OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.